The first and only* deep brain stimulation system with sensing, directionality, and advanced programming for movement disorders like Parkinson’s and epilepsy
- Percept™ RC is the smallest and thinnest dual channel‡ rechargeable neurostimulator available for DBS
- The latest advancement introduced in India is the only* technology that can record brain signals, empowering healthcare providers to tailor therapy to each patient’s evolving needs
Mumbai, 5th December 2024: Medtronic, a global leader in healthcare technology, has received FDA approval for its Percept™ RC and is now available in India. This is the smallest and thinnest dual channel neurostimulator available for Deep Brain Stimulation (DBS) system, marking the latest advancement in the Percept ™ family. This new rechargeable neurostimulator compliments Medtronic’s existing portfolio of devices. The Percept™ neurostimulators are the only* DBS systems available with integrated sensing capabilities, allowing physicians to deliver highly personalized treatments for patients with movement disorders such as Parkinson’s disease, essential tremor, dystonia, and epilepsy.
Equipped with BrainSense™ technology, the Percept™ RC captures and records brain signals, offering valuable insights that allow healthcare providers to adapt and personalize therapy to meet each patient’s changing needs. Its rechargeable battery, powered by Medtronic’s patented technology, provides an impressive 15-year plus service life6 with minimal fade, ensuring consistent and reliable performance over time. Unlike other devices, the Percept™ RC recharges rapidly, achieving a 10% to 90% charge in under an hour, delivering convenience and dependability for patients.
Mr. Prateek Tiwari, Sr. Director, Neuroscience and Specialty Therapies, Medtronic India said, “We are elated to bring the latest innovation in DBS technology to patients and clinicians in India. This cutting-edge solution aligns with the increasing demand for advanced healthcare innovations and promises a transformative impact on the treatment of complex neurological disorders. With its ability to deliver highly personalized, data-driven therapy, our new rechargeable Percept™ RC neurostimulator with BrainSense™ technology has the potential to significantly improve patient outcomes and offer a new hope for those managing the challenges of chronic neurological conditions. We look forward to empowering healthcare providers in India to set a new standard in precision care and enhanced quality of life.”
Deep brain stimulation (DBS) uses a surgically implanted device, similar to a cardiac pacemaker. Medtronic Percept™ neurostimulators send electrical signals through thin wires to specific brain regions affected by neurological conditions like Parkinson’s disease.
Nearly 70 percent of all DBS-eligible patients are estimated to require an MRI as part of their essential care1. Medtronic offers full-body MR Conditional DBS systems for patients to have safe scans anywhere on the body under specific conditions‡.
Percept™ offers greater freedom and scan access for patients with 3T scans and best-in-class 1.5T MRI scan labeling5-7. Medtronic has the only* DBS system that allows patients to have stimulation on in bipolar mode during an MRI2-4. ‡ In addition, the Percept™ neurostimulators are engineered to allow for future software updates designed for the Percept™ platform without a neurostimulator device exchange.
Since 1987, Medtronic has served over 180 thousand patients in more than 70 countries with its life-changing DBS therapy5. In India Medtronic DBS systems are serving patients for over 25 years now5.
